Pharvaris N.V. (PHVS)
NASDAQ:PHVS
Want to see PHVS full AI Analyst Report?
Top Page
Pharvaris
(NASDAQ:PHVS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$31.00
▲(8.47% Upside)
Action:Reiterated
Date:05/15/26
The score is primarily held back by weak financial performance driven by no revenue, widening losses, and rising cash burn (funding risk), partially offset by low balance-sheet leverage. Technicals are supportive with price above major moving averages and positive MACD, while valuation remains constrained by ongoing losses and no dividend.
Positive Factors
Near-term regulatory and pivotal milestones (NDA filing, Phase 3 topline)
Progress toward a U.S. NDA and an upcoming pivotal CHAPTER-3 topline readout materially reduces development risk versus earlier stages. Success at these milestones would transition Pharvaris from R&D execution to regulatory submission and potential approval, underpinning durable commercial opportunity in HAE.
Negative Factors
Sustained and rising cash burn
Persistent and increasing negative free cash flow creates ongoing funding needs and elevates execution risk. Over months, high burn compels dependence on capital markets or partnerships, constraining strategic flexibility and potentially forcing dilutive financings that affect long-term shareholder value if clinical timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Near-term regulatory and pivotal milestones (NDA filing, Phase 3 topline)
Progress toward a U.S. NDA and an upcoming pivotal CHAPTER-3 topline readout materially reduces development risk versus earlier stages. Success at these milestones would transition Pharvaris from R&D execution to regulatory submission and potential approval, underpinning durable commercial opportunity in HAE.
Read all positive factors
Pharvaris (PHVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.93B
Dividend YieldN/A
Average Volume (3M)338.30K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue GrowthN/A
EPS Growth-5.22%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.83
Shares Outstanding65,407,820
10 Day Avg. Volume441,214
30 Day Avg. Volume338,302
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.24K
Enterprise Value/Ebitda-8.30
Forecast
1Y Price Target
$48.04Price Target Upside68.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Pharvaris Business Overview & Revenue Model
Company Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinic...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Pharvaris does not have a stable, ongoing product-revenue stream from marketed drugs (null). Its cash inflows are primarily generated through financing activities rather than operations, including: (1...
Pharvaris Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -169.40M | -145.59M | -96.66M | -86.56M | -54.06M |
| Net Income | -175.70M | -134.22M | -100.88M | -76.33M | -42.73M |
Balance Sheet | |||||
| Total Assets | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M |
| Cash, Cash Equivalents and Short-Term Investments | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M |
| Total Debt | 776.80K | 861.47K | 238.91K | 436.82K | 250.18K |
| Total Liabilities | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M |
| Stockholders Equity | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M |
Cash Flow | |||||
| Free Cash Flow | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M |
| Operating Cash Flow | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M |
| Investing Cash Flow | -164.62K | -538.09K | -89.98K | -124.30K | -130.03K |
| Financing Cash Flow | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M |
Pharvaris Technical Analysis
Positive
28.58
Price Trends
28.42
Positive
27.57
Positive
25.57
Positive
Market Momentum
0.38
Positive
49.83
Neutral
12.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 28.58 is below the 20-day moving average (MA) of 29.77, above the 50-day MA of 28.42, and above the 200-day MA of 25.57, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 12.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.
Pharvaris Risk Analysis
Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our articles of association designate specific courts as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Q4, 2023
2.
to successfully commercialize our product candidates, or experience significant delays in doing so, our business, financial condition, results of operations and prospects would be materially adversely affected. Q4, 2023
Pharvaris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $2.22B | -0.80 | 123.57% | ― | 75.92% | -569.22% | |
56 Neutral | $3.53B | -17.21 | -32.55% | ― | ― | -7.28% | |
52 Neutral | $1.93B | -10.01 | -67.38% | ― | ― | -5.22% | |
52 Neutral | $2.43B | -6.71 | -50.72% | ― | -88.54% | -58.13% | |
52 Neutral | $1.82B | -4.76 | -60.70% | ― | 23382.78% | 7.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.33B | -2.39 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
PHVS
Pharvaris
29.45
13.05
79.57%
BCRX
BioCryst
8.74
-1.33
-13.21%
CLDX
Celldex
30.90
10.95
54.89%
VRDN
Viridian Therapeutics
17.63
3.97
29.06%
EWTX
Edgewise Therapeutics
32.82
18.23
124.95%
BHVN
Biohaven Ltd.
8.85
-6.85
-43.63%
Pharvaris Corporate Events
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
May 12, 2026
Pharvaris reported first-quarter 2026 results on May 12, 2026, highlighting continued investment in late-stage trials of its oral angioedema drug deucrictibant and preparations for commercialization. The company closed a $132 million underwritten ...
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
May 11, 2026
On May 8, 2026, Pharvaris N.V. signed an underwriting agreement with a syndicate led by Morgan Stanley and Leerink Partners to issue and sell 4,455,863 ordinary shares, including the full exercise of the underwriters’ option, in an underwrit...
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
Apr 2, 2026
On April 2, 2026, Pharvaris reported fourth-quarter and full-year 2025 results that underline its transition toward late-stage commercialization in rare angioedema disorders. The company closed 2025 with €291.7 million in cash and cash equiv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.